Some combinations of long-term health conditions linked to worse quality of life
Peer-Reviewed Publication
Updates every hour. Last Updated: 5-Jul-2025 17:10 ET (5-Jul-2025 21:10 GMT/UTC)
A new study, co-led by a University of Massachusetts Amherst researcher, set out to identify the most effective strategies for helping people quit vaping. The findings, published today in the Cochrane Database of Systematic Reviews, suggest that varenicline, a prescription medication often used to help people stop smoking, and text message-based interventions can help people quit.
People who drink coffee in the morning have a lower risk of dying from cardiovascular disease and a lower overall mortality risk compared to all-day coffee drinkers, according to research published in the European Heart Journal.
Children and young people with high levels of mental health needs are struggling to receive the help they need, or to have their difficulties recognised, according to a new study.
The STADIA trial, which is published in the Journal of Child Psychology and Psychiatry, was led by experts from the School of Medicine at the University of Nottingham, and was funded by the National Institute for Health and Care Research (NIHR).
The large study, which spans different parts of England, involved 1,225 children and young people with emotional difficulties who had been referred to Child and Adolescent Mental Health Services (CAMHS) for help, and followed them up over 18 months to see how they got on.
Cells degrade components that are no longer needed through autophagy. New results show that a weak molecular interaction is essential for this process.
By modifying this interaction, it is possible to artificially trigger autophagy, which could then enable the degradation of deposits in neurodegenerative diseases such as Alzheimer's, or support cancer therapies.
The study was published in the journal Nature Cell Biology and was led by Prof. Dr. Claudine Kraft, a member of the CIBSS Cluster of Excellence at the University of Freiburg, and Dr. Florian Wilfling from the Max Planck Institute of Biophysics in Frankfurt.